A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

NCT01636557 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: Sirukumab
DRUG: Midazolam
DRUG: Warfarin
DRUG: Vitamin K
DRUG: Omeprazole
DRUG: Caffeine

Sponsor

Janssen Research & Development, LLC